1. Scrip
  2. >>Business
  3. >>Deals

Spruce Pivots After Pipeline Failure With BioMarin Tralesinidase Deal

Sanfilippo Syndrome Drug Set For ’26 Filing

 
• By Sushmita Panda

After dropping its lead program in December, Spruce has been exploring strategic options – and thinks it has a de-risked path for MPS IIIB therapy tralesinidase from BioMarin.

DNA
The autosomal recessive disorder affects one in 200,000 newborns. (Shutterstock)

Spruce Biosciences is securing rights to a shelved BioMarin rare disease candidate in a bid to revive its pipeline – but it will need additional funding to get that program to market.

On 15 April, the San Francisco biotech obtained exclusive global rights to tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo syndrome type B (MPS IIIB) from BioMarin. Spruce will pay BioMarin up to $22

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Rare Diseases